Immune modulating effects and safety of Vvax001; different dosages will be tested in patients with a history of (pre) malignant cervical lesions.

Vvax001 is a therapeutic cancer vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.

Inclusion Criteria:

• A history of CIN II and III OR cervical cancer
• Minimally 12 weeks after completion of treatment
• Age of 18 years and older
• Baseline laboratory findings; adequate hepatic, renal ,and bone marrow function, HIV- and HBV-negative
• Patients of child-bearing potential should test negative using a serum pregnancy test and agree to utilize effective contraception during the entire treatment and follow-up period of the study
• Written informed consent according to local guidelines

Exclusion Criteria:

• Prior treatment with immunotherapeutic agents against HPV
• History of an autoimmune disease or other systemic intercurrent disease that might affect the immunocompetence of the patient, or current or prior use (4 weeks before start of the study) of high dose immunosuppressive therapy.
• History of a second malignancy except curatively treated low-stage tumors with a histology that can be differentiated from the cervical cancer type
• Participation in a study with another investigational drug within 30 days prior to the enrolment in this study
• Any condition that in the opinion of the investigator could interfere with the conduct of the study